0JXZ Stock Chart & Stats
€24.70
€0.10(0.38%)
At close: 4:00 PM EST
€24.70
€0.10(0.38%)
Day’s Range― - ―
52-Week Range€22.38 - €32.70
Previous CloseN/A
Volume42.14K
Average Volume (3M)9.16K
Market Cap
€1.60B
Enterprise Value-€394.90
Total Cash (Recent Filing)€2.98B
Total Debt (Recent Filing)€6.43M
Price to Earnings (P/E)3.2
Beta0.47
Next Earnings
Nov 12, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.39
Shares Outstanding65,897,070
10 Day Avg. Volume4,733
30 Day Avg. Volume9,162
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.00Price Target Upside-10.93% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-2.95
Revenue Forecast (FY)€24.65M
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained, very high EBIT and net margins indicate the company extracts strong value from revenue, implying durable pricing power or low incremental cost. This margin profile supports reinvestment and resilience across cycles if revenue stabilises, boosting long-term earnings capacity.
Exceptionally Conservative Balance SheetMinimal debt and a large equity base materially reduce refinancing and solvency risk, providing financial runway for R&D and operations. Conservative capital structure gives flexibility to fund development or absorb shocks without near-term liquidity stress.
Very High Gross MarginsExceptionally high gross margins point to low incremental product costs or high-value services, enabling scalable profitability as sales grow. This structural margin advantage supports long-term operating leverage and the ability to fund commercial or pipeline investments.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business is not self-funding and depends on the balance sheet or external capital to sustain operations and investment. Over months this elevates financing risk and can force dilution or spending cuts if losses persist.
Revenue VolatilityUneven top-line performance undermines forecasting and capital allocation. Volatile revenue complicates scaling and raises the risk that current profitability is cyclical, making long-term planning and consistent returns harder to sustain without more predictable growth.
Historical Earnings VolatilityPast swings in earnings imply operating results can revert, putting pressure on ROE and investor expectations. If the company cannot stabilize revenues or margins, improved ROE and profitability may prove temporary, increasing execution risk over the medium term.
Galapagos News
0JXZ FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest share price was €22.38 and its highest was €32.70 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is €1.60B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is Nov 12, 2026 which is in 88 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on Aug 10, 2026. The company reported -€0.2 earnings per share for the quarter, missing the consensus estimate of -€0.123 by -€0.077.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Overvalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.4.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of -€0.2 in its last earnings report, missing expectations of -€0.123. Following the earnings report the stock price went up 3.418%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in GB:0JXZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
0JXZ Stock 12 Month Forecast
Average Price Target
€22.00
▼(-10.93% Downside)